Protocol number: cv-9104-004. study name: a randomized double-blind placebo-controlled phase i/ii trial of rnactive®-derived cancer vaccine (cv9104) in asymptomatic or minimally symptomatic patients with metastatic castrate-resistant prostrate cancer